Search Results - "De la Fuente Burguera, A."

EFFICACY AND SAFETY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB AS FRONTLINE TREATMENT FOR INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA. RESULTS OF THE GELTAMO IMCL‐2015 STUDY by Giné, E., De la Cruz, F., Ubieto, A. Jiménez, Jiménez, J. López, García‐Sancho, A. Martín, Terol, M. J., González‐Barca, E., Casanova, M., De la Fuente Burguera, A., Niebla, A. Marín, Prat, A. Muntanola, González‐López, T. J., Aymerich, M., Setoain, X., Cortés‐Romera, M., Rotger, A., Medina, A., García‐Sanz, R., Campo, E., López‐Guillermo, A.

Get full text

P508: REAL LIFE EXPERIENCE USING FRONT‐LINE CPX‐351 FOR THERAPY‐RELATED AND AML‐MRC: RESULTS FROM THE SPANISH PETHEMA REGISTRY by Bernal, T., Rad, G., Laiglesia, A., Benavente, C., Garcia Noblejas, A., Garcia Belmonte, D., Riaza, R., Salamero, O., Foncillas, A., Roldán, A., Noriega Concepcion, V., Perez de Oteyza, J., Bergua Burgues, J. M., Lorente de Uña, S., Fuente Burguera, A., Garcia Perez, M. J., Lopez Lorenzo, J. L., Martinez, P., Alaez, C., Callejas, M., Martinez Chamorro, C., Rifon Roca, J., Amador Barciela, L., Lopez, M., Gomez Correcha, K., Lavilla Rubiera, E., Amigo, M. L., Vall‐Llovera, F., Garrido, A., Garcia Fortes, M., Miguel Llorente, D., Aules Leonardo, A., Cervero, C., Coll Jorda, R., Perez Encinas, M., Polo Zarzuela, M., Martinez Cuadron, D., Montesinos, P.

Get full text

648TiP Reduction of methotrexate (MTX) levels after glucarpidase in patients with diffuse large b cell lymphoma (DLBCL) at risk of central nervous system (CNS) involvement who receive cycles of HDMTX: An open-label, interventional, non-randomized, phase II, pilot, multicenter study by de la Fuente Burguera, A., Peñalver Parraga, F.J., Cordoba Mascunano, R., Herrera, P., Olave, M.T., Martiniez Chamorro, C., Jarque, I., Estevez Fernandez, M.

Get full text

PB1747 ASSESSMENT OF FLT3 MUTATION IN ACUTE MYELOID LEUKEMIA: RESULTS OF A SPANISH DELPHI PANEL SURVEY by Gómez‐Casares, M.T., De la Fuente Burguera, A., Barragán, E., Calasanz, M.J., Jiménez Velasco, A., Sanz, M.Á., Esteve, J., Serrano, J., Pratcorona, M., Sierra, J.

“…Background: Despite the value of FLT3 as selective marker that drives therapy and current guidelines recommendations of FLT3 testing in all patients with AML,…”
Get full text